ERr 731 is a dry extract of the root of rhapontic rhubarb, Rheum rhaponticum. It is sold in Germany as Phytoestrol N and in the US as Estrovera. One tablet holds 4 mg of the extract. This page covers its label amounts and one trial against a dummy tablet in women around menopause.
Terms and sources
- dry extract
- 16 to 26 parts of root give 1 part of extract, made with calcium oxide and water. Heger et al., Frontiers in Pharmacology, 2026.
- Estrovera
- Metagenics is named as the US distributor of Estrovera. Chang et al., Integrative Medicine, 2016.
- 4 mg
- Each 400 mg enteric-coated tablet. Heger et al., Frontiers in Pharmacology, 2026.
ERr 731 in the body
ERr 731 is not a nutrient, and the body has no daily requirement for it. Its trials in women around menopause measure menopausal symptom scores and hot flashes.
A 2026 report by the trial sponsor's staff names rhaponticin and desoxyrhaponticin as its main compounds. The same report describes the extract as rich in stilbenes, unlike rhubarb preparations with anthraquinones.
Terms and sources
- the trial sponsor's staff
- The authors own or work for Health Research Services GmbH, which funded the trial they report. The report's own Funding section says the report was not funded. Heger et al., Frontiers in Pharmacology, 2026.
- desoxyrhaponticin
- With rhapontigenin and desoxyrhapontigenin, the same compounds without their sugar part. Heger et al., Frontiers in Pharmacology, 2026.
- stilbenes
- Plant compounds with a structure related to resveratrol. Heger et al., Frontiers in Pharmacology, 2026.
A 2016 report by staff of its manufacturer, two firms selling it and a research contractor counted side-effect reports. In Germany, about 140 million daily doses were placed on the market from 1993 to June 2014. In that time, 124 side-effect reports were recorded. The 124 reports listed 215 reactions; the most common were hypersensitivity, 74, and gastrointestinal symptoms, 47. All German reports but one were rated not serious. The serious one was a hospital stay for a sharp rise in liver enzymes.
Terms and sources
- A 2016 report
- Authors: two staff of its US distributor, Metagenics. Also the directors of its manufacturer and of a research contractor, and the pharmacovigilance officer of Dr. Loges + Co. One author declares no conflict. The report does not state who paid. Chang et al., Integrative Medicine, 2016.
- 124 side-effect reports
- Reports recorded by the two German authorization holders, for Phytoestrol N and femi-loges. Chang et al., Integrative Medicine, 2016.
- 215 reactions
- Counted as reactions; one report can hold more than one. Chang et al., Integrative Medicine, 2016.
- a hospital stay
- The product was stopped. The authors write that causality was “not assessable.” Chang et al., Integrative Medicine, 2016.
In North America, about 13 million tablets were sold from 2009 to June 2014. Buyers there made 79 complaints of a physical response. The main ones were gastrointestinal symptoms, 23, and the product not working as suggested, 22. The report names one serious case, “the occurrence of endometrial cancer during the use of the extract.” The authors judge a link to the extract unlikely.
Terms and sources
- 79 complaints
- Complaints recorded by the US distributor of Estrovera. Chang et al., Integrative Medicine, 2016.
- one serious case
- In full: “One serious case was identified, in which the occurrence of endometrial cancer during the use of the extract had been reported.” The authors write that information was insufficient to judge whether any complaint was related to the extract. Chang et al., Integrative Medicine, 2016.
- unlikely
- They write: “a relationship between the development of endometrial cancer and the intake of the extract in the current case seems unlikely.” Chang et al., Integrative Medicine, 2016.
The authors note that “underreporting is a well-known limitation of spontaneous reporting.” The report’s authors write that the extract “is contraindicated for individuals with any known or suspected estrogen-dependent cancer.” These counts come from reports sent to the companies, not from a trial.
Terms and sources
- underreporting
- Chang et al., Integrative Medicine, 2016.
- contraindicated
- The article says this is stated in the package insert. “The extract is contraindicated for individuals with any known or suspected estrogen-dependent cancer, as stated in the package’s insert.” Chang et al., Integrative Medicine, 2016.
- not from a trial
- From the PMC full text. Chang et al., Integrative Medicine, 2016.
Where ERr 731 comes from
Rheum rhaponticum is also called garden rhubarb. Its stalks are eaten, and ERr 731 is made from its root. Medicinal rhubarb roots come from other species, such as Rheum palmatum and Rheum officinale.
Terms and sources
- garden rhubarb
- Püssa et al., Phytochemical Analysis, 2009, call it garden or dietary rhubarb.
- stalks are eaten
- Uchibayashi, Yakushigaku Zasshi, 2001, English abstract: Rheum rhaponticum is the edible rhubarb.
- other species
- Uchibayashi, 2001, names Rheum palmatum, Rheum tanguticum, Rheum officinale and Rheum coreanum as medicinal rhubarbs.
One analysis found many stilbenes in rhapontic rhubarb root, derived from piceatannol, resveratrol, rhapontigenin and desoxyrhapontigenin. The same analysis also found hydroxyanthraquinones and their glycosides in the root.
Terms and sources
- One analysis
- Root and stalk samples, analysed by liquid chromatography and mass spectrometry. Stalks showed a similar profile with lower amounts. Püssa et al., Phytochemical Analysis, 2009.
Published studies of ERr 731
The trial below compared ERr 731 with a dummy tablet in women around menopause.
Some studies are not listed; the note above says which and why.
1 trial in women around menopause: it found a difference.
The trial selected women by a menopausal symptom score, not by a diagnosis. Not listed: a second trial of 109 women. A correction to it was published, and we could not read it. Also not listed: later reports of both trials, including open follow-ups in which every woman took ERr 731. Also not listed: two open studies without a dummy group. Also not listed: a review that counts each trial twice. Also not listed: reviews of several herbs or treatments, including medicines, and a study of prescription records.
Our one-line summary comes first. The original is on PubMed.
Show the study
Over 12 weeks, symptom scores fell from 27.0 to 12.4 with ERr 731, and to 24.0 with a dummy tablet.
Trial · 112 people · 12 weeks · funding not stated
Kaszkin-Bettag et al., Alternative Therapies in Health and Medicine, 2009
Terms and sources
- symptom scores
- Menopause Rating Scale total score, the main outcome, in 112 women around menopause. The difference was statistically significant. The abstract also gives P < .0001 for each scale item and for hot flashes. It does not say if these compare the groups. Heger et al., 2026, a later report of this trial, gives four more ratings in 89 women. At 12 weeks, three differed from the dummy group; one did not. It also reports mood ratings; the article text gives no test between groups for them.
- ERr 731
- One enteric-coated tablet a day, with 4 mg of dry extract. Side effects: 11 events in 5 of 56 women, against 3 events in 3 of 56 with the dummy tablet. The 2009 abstract does not state funding. A 2026 report of this trial names Health Research Services GmbH, its authors' firm, as funder. That report's Funding section says the report itself was not funded. Heger et al., 2026.
- a dummy tablet
- A dummy tablet, one a day; the abstract does not describe it further.
Study · Abstract only · about 2 min to read
Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
112 women around menopause with menopausal symptoms took part at several centers. Each day for 12 weeks, they took one enteric-coated ERr 731 tablet or a dummy tablet. Menopause Rating Scale total scores fell from 27.0 to 12.4 with ERr 731. With the dummy tablet, they fell from 27.0 to 24.0. The difference was statistically significant. Five women with ERr 731 reported 11 side effects, and three with the dummy tablet reported three. Funding: not stated in the abstract.
Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.